Morgan Stanley Reiterates Buy on argenx SE with $1,180 Target
Morgan Stanley maintains its buy rating on argenx SE, setting a target price of $1,180, a 32.79% upside from the current price.
Key Points
- Morgan Stanley analyst Matthew Harrison reiterated a buy rating for argenx SE (ARGX) with a target price of $1,180 as of June 24, 2026.
- Morgan Stanley's $1,180 price target implies 32.79% upside from argenx SE's ($ARGX) current $888.65 share price.
- argenx SE's stock traded at $853.4 on Wednesday, with a market cap of approximately $56.5 billion and a P/E ratio of 40.2.
- Other analysts from firms like Wells Fargo and Evercore ISI Group also maintain buy ratings, with various price targets up to $1,291.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley's analyst Matthew Harrison reiterated his buy rating on argenx SE (NasdaqGS: ARGX) on June 24, 2026. He set a price target of $1,180 for the biotechnology company. This comes as shares of argenx traded at $853.4 on Wednesday.
Morgan Stanley vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
argenx SE Stock Down 13.2%
Shares of NasdaqGS:ARGX traded near $853.4 on Wednesday. argenx SE boasts a market cap of approximately $56.5 billion, with a P/E ratio of 40.2 and a forward P/E of 24.7. The stock has experienced a 52-week low of $510.06 and a high of $934.62, with a 50-day moving average of $822.67 and a 200-day moving average of $811.28. Its beta is slightly negative at -0.033, indicating low volatility compared to the market.
$ARGX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in argenx SE
FMR LLC trimmed its holdings in argenx by 601,285 shares, bringing its total to 4,991,034 shares worth about $3.64 billion, a 10.8% decrease. Meanwhile, PRICE T ROWE ASSOCIATES INC added 12,631 shares, holding 3,374,955 shares valued at $2.46 billion, a modest 0.4% increase. JANUS HENDERSON GROUP PLC increased its stake by 83,568 shares to 2,541,732 shares, valued at $1.85 billion, marking a 3.4% increase. CAPITAL WORLD INVESTORS significantly boosted its position by 339,982 shares to 2,256,216 shares, worth about $1.65 billion, reflecting a 17.7% increase. ARTISAN PARTNERS LIMITED PARTNERSHIP reduced its position by 288,960 shares, ending with 1,467,982 shares valued at $1.07 billion, a 16.4% decrease.
Analysts Set New Price Targets
On June 24, 2026, Morgan Stanley maintained its buy rating on argenx SE with a $1,180 price target. Wells Fargo also maintained a buy rating with a higher target of $1,291 set on June 1, 2026. Evercore ISI Group kept its buy rating with a target of $1,059 on May 15, 2026. Guggenheim maintained a buy rating with a $1,135 target on May 8, 2026. Overall, the consensus among 22 analysts is a strong buy with a mean target price of $1,018.14, and targets ranging from $679.68 to $1,269.90.
About argenx SE
argenx SE is a biotechnology company based in Amsterdam, Netherlands. It develops therapies for autoimmune diseases and offers products like VYVGART for treating generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP). The company also works on efgartigimod for various autoimmune conditions and has several pipeline candidates targeting different diseases. argenx collaborates with companies like Zai Lab and AbbVie to advance its therapies globally. Led by CEO Ms. Karen Massey, argenx employs around 1,863 people.
Bottom Line
Morgan Stanley's reaffirmation of a buy rating with a $1,180 target reflects confidence in argenx SE's growth prospects. The stock's recent performance and institutional activity indicate active interest in its potential. This analysis is based on backward-looking data from the latest analyst reports and may not represent current market conditions.
Get argenx SE alerts
New 13F filings, insider trades, and analyst moves on $ARGX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.